AU2002300359A1 - Fusion Protein Having Enhanced in vivo Activity of Erythropoietin - Google Patents
Fusion Protein Having Enhanced in vivo Activity of ErythropoietinInfo
- Publication number
- AU2002300359A1 AU2002300359A1 AU2002300359A AU2002300359A AU2002300359A1 AU 2002300359 A1 AU2002300359 A1 AU 2002300359A1 AU 2002300359 A AU2002300359 A AU 2002300359A AU 2002300359 A AU2002300359 A AU 2002300359A AU 2002300359 A1 AU2002300359 A1 AU 2002300359A1
- Authority
- AU
- Australia
- Prior art keywords
- erythropoietin
- enhanced
- fusion protein
- vivo activity
- vivo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR2001-74975 | 2001-11-29 | ||
KR10-2001-0074975A KR100467750B1 (en) | 2001-11-29 | 2001-11-29 | Fusion protein having the enhanced in vivo activity of erythropoietin |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002300359A1 true AU2002300359A1 (en) | 2003-06-12 |
AU2002300359B2 AU2002300359B2 (en) | 2004-12-23 |
Family
ID=36821313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002300359A Ceased AU2002300359B2 (en) | 2001-11-29 | 2002-07-30 | Fusion Protein Having Enhanced in vivo Activity of Erythropoietin |
Country Status (23)
Country | Link |
---|---|
US (1) | US7098318B2 (en) |
EP (1) | EP1319712B1 (en) |
JP (1) | JP3860097B2 (en) |
KR (1) | KR100467750B1 (en) |
CN (1) | CN100390201C (en) |
AR (1) | AR036384A1 (en) |
AT (1) | ATE460483T1 (en) |
AU (1) | AU2002300359B2 (en) |
BR (1) | BRPI0203394B1 (en) |
CA (1) | CA2394572C (en) |
DE (2) | DE60235603D1 (en) |
ES (1) | ES2339426T3 (en) |
FR (1) | FR2832716B1 (en) |
GB (1) | GB2382580B (en) |
IT (1) | ITMI20021803A1 (en) |
MX (1) | MXPA02008131A (en) |
MY (1) | MY122935A (en) |
NZ (1) | NZ520442A (en) |
RU (1) | RU2225220C1 (en) |
SG (1) | SG117416A1 (en) |
TW (1) | TWI237056B (en) |
WO (1) | WO2003046013A1 (en) |
ZA (1) | ZA200206172B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
EA010650B1 (en) * | 2003-09-29 | 2008-10-30 | Уоррен Фармасьютикалз, Инк. | Tissue protective cytokines for the treatment and preservations of sepsis and the formation of adhesions |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US7553940B2 (en) * | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting EPO polypeptides and derivatives thereof and methods thereof |
US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
CN101863982A (en) * | 2009-04-17 | 2010-10-20 | 哈药集团生物工程有限公司 | Fusion protein for increasing blood platelets and preparation method thereof |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
CN103864913A (en) * | 2012-12-18 | 2014-06-18 | 联亚生技开发股份有限公司 | Recombinant protein |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
IL301728A (en) | 2015-06-19 | 2023-05-01 | Opko Biologics Ltd | Long-acting coagulation factors and methods of producing same |
CA3030533A1 (en) | 2016-07-11 | 2018-01-18 | Oren HERSHKOVITZ | Long-acting coagulation factor vii and methods of producing same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0461200T3 (en) * | 1989-02-21 | 1997-03-10 | Univ Washington | Modified forms of reproductive hormones |
AU5355790A (en) * | 1989-04-19 | 1990-11-16 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
ZA946122B (en) * | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
SG47030A1 (en) * | 1994-01-03 | 1998-03-20 | Genentech Inc | Thrombopoietin |
ITFI940106A1 (en) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | HYBRID MOLECULE OF GM-CSF-L-EPO OR EPO-L-GM-CSF FORMULA FOR ERYTHROPOIETIC STIMULATION |
JPH11500308A (en) * | 1995-02-03 | 1999-01-12 | ジー.ディー.サール アンド カンパニー | New c-MPL ligand |
AU8182298A (en) * | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
US6242570B1 (en) * | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
BR9812267B1 (en) * | 1997-07-14 | 2013-11-26 | Recombinant Growth Hormone. | |
US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
AU3538799A (en) * | 1998-04-30 | 1999-11-23 | Kirin Brewery Company, Limited | Human thrombopoietin mutants |
CA2379388C (en) * | 1999-07-13 | 2012-05-29 | George N. Cox, Iii | Immunoglobulin fusion proteins |
CA2391080A1 (en) * | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
-
2001
- 2001-11-29 KR KR10-2001-0074975A patent/KR100467750B1/en not_active IP Right Cessation
-
2002
- 2002-07-24 CA CA002394572A patent/CA2394572C/en not_active Expired - Fee Related
- 2002-07-26 WO PCT/KR2002/001420 patent/WO2003046013A1/en active Search and Examination
- 2002-07-26 TW TW091116686A patent/TWI237056B/en not_active IP Right Cessation
- 2002-07-30 NZ NZ520442A patent/NZ520442A/en not_active IP Right Cessation
- 2002-07-30 AU AU2002300359A patent/AU2002300359B2/en not_active Ceased
- 2002-07-30 MY MYPI20022857A patent/MY122935A/en unknown
- 2002-08-01 DE DE60235603T patent/DE60235603D1/en not_active Expired - Lifetime
- 2002-08-01 AT AT02016953T patent/ATE460483T1/en active
- 2002-08-01 EP EP02016953A patent/EP1319712B1/en not_active Expired - Lifetime
- 2002-08-01 ES ES02016953T patent/ES2339426T3/en not_active Expired - Lifetime
- 2002-08-01 SG SG200204673A patent/SG117416A1/en unknown
- 2002-08-01 DE DE10235248A patent/DE10235248B4/en not_active Expired - Fee Related
- 2002-08-02 FR FR0209867A patent/FR2832716B1/en not_active Expired - Lifetime
- 2002-08-02 ZA ZA200206172A patent/ZA200206172B/en unknown
- 2002-08-06 GB GB0218252A patent/GB2382580B/en not_active Expired - Fee Related
- 2002-08-08 IT IT001803A patent/ITMI20021803A1/en unknown
- 2002-08-20 BR BRPI0203394A patent/BRPI0203394B1/en not_active IP Right Cessation
- 2002-08-21 MX MXPA02008131A patent/MXPA02008131A/en active IP Right Grant
- 2002-08-23 CN CNB021301557A patent/CN100390201C/en not_active Expired - Fee Related
- 2002-08-29 US US10/230,454 patent/US7098318B2/en not_active Expired - Lifetime
- 2002-08-30 RU RU2002123438/15A patent/RU2225220C1/en not_active IP Right Cessation
- 2002-08-30 AR ARP020103279A patent/AR036384A1/en not_active Application Discontinuation
- 2002-08-30 JP JP2002253938A patent/JP3860097B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002300734A1 (en) | Fusion protein having enhanced in vivo erythropoietin activity | |
AU2002300359A1 (en) | Fusion Protein Having Enhanced in vivo Activity of Erythropoietin | |
ZA200206172B (en) | Fusion protein having enhanced in vivo activity of erythropoietin. | |
AU2002363296A1 (en) | Human secreted proteins | |
HUP0401300A3 (en) | Bifunctional fusion proteins with glucocerebrosidase activity | |
AU6058500A (en) | Fusion protein and uses thereof | |
AU2002329172A1 (en) | Human secreted proteins | |
AU1608201A (en) | Human zven proteins | |
AU2002251999A1 (en) | Methods and compositions for the construction and use of fusion libraries using computational protein design methods | |
AU2067501A (en) | Human oxidoreductase proteins | |
AU3923000A (en) | Agp-1 fusion protein compositions and methods | |
AU2002305903A1 (en) | Carbohydrate-associated proteins | |
AU2002322416A1 (en) | Gfp fusion proteins and their use | |
AU2002311620A1 (en) | Methods of making and using expression constructs for the expression of recombinant proteins | |
AU2002354363A1 (en) | Method of activating protein | |
AU2003267356A1 (en) | Proteins having polysaccharidase activity | |
AU2002240921A1 (en) | Medane genes and proteins | |
AU2002357850A1 (en) | Neurotransmission-associated proteins | |
AU2002360333A1 (en) | Human angiomotin-like protein 1 | |
AU2002257630A1 (en) | Human mrp5-like protein | |
AU2002351616A1 (en) | Lipase genes and proteins | |
AU2002242870A1 (en) | Nucleic acids encoding human est1 proteins | |
AU2002357873A1 (en) | Carbohydrate-associated proteins | |
AU2002326909A1 (en) | Neurotransmission-associated proteins | |
AU2002357145A1 (en) | Therapeutic protein and nucleic acid |